<DOC>
	<DOCNO>NCT01563731</DOCNO>
	<brief_summary>Stroke one major cause mortality , disease burden worldwide , residual disability cognitive decline . Although blood pressure lower clearly show effective mean primary secondary prevention stroke , systolic blood pressure ( SBP ) level achieve treatment order optimize prevention result unknown , whether SBP level lower usually recommend accompany reduced benefit undecided yet . Likewise , low-density lipoprotein cholesterol ( LDL-C ) lower statin show associated primary secondary stroke prevention , whether intense lower benefit unknown . The Stroke Hypertension Optimal Treatment Trial ( ESH-CHL-SHOT ) factorial 3 x 2 arm , multicenter , randomize clinical trial design test hypothesis elderly patient high risk recurrent stroke ( previous recent stroke TIA ) antihypertensive treatment program aim reduce SBP usually recommend value ( &lt; 145 135 mmHg ) , low goal ( &lt; 135 125 mmHg ) even low value ( &lt; 125 mmHg ) result progressively great reduction recurrent stroke , incidence cardiovascular outcomes cognitive decline . Parallely , preventive efficacy less intense LDL-C reduction test outcome .</brief_summary>
	<brief_title>Optimal Blood Pressure Cholesterol Targets Preventing Recurrent Stroke Hypertensives</brief_title>
	<detailed_description>ESH-CHL-SHOT randomize 7500 participant age &gt; = 65 year SBP &gt; = 140 mmHg antihypertensive therapy , present stroke TIA , within 1 6 month randomization . The trial investigate 1. effect randomization antihypertensive treatment different intensity , aim three different SBP target . SBP target &lt; 145 135 , &lt; 135 125 , &lt; 125 mmHg , approximate mean inter-target difference 8 mmHg ; 2. effect randomization lipid lower treatment different intensity , aim two different LDL-C target . Targets 2.8 1.8 mmol/l ( 110 70 mg/dl ) &lt; 1.8 mmol/l ; 3. possible interaction antihypertensive lipid-lowering treatment . The primary hypothesis recurrent stroke rate 25 % low low v intermediate SBP target group , 25 % low intermediate v high SBP target group , 20 % low low v high LDL-C target group . Sample size calculate provide 80 % power significance 5 % correction repetitive measurement assumption stroke incidence 4 % per year high SBP target group . Participants recruit approximately 250 clinic Europe ( 2500 patient ) China ( 5000 patient ) 2-year period , follow average 4 year 925 recurrent stroke occur . Arms assign intervention 1 . Antihypertensive treatment design assign treatment Participants randomly allocate one three different sit SBP target : 1 . &lt; 145 135 mmHg 2 . &lt; 135 125 mmHg 3 . &lt; 125 mmHg possibly achieve within 3 month subsequently maintain within target window . Investigators free choose drug ( among approve country ) administer individual patient . It expect patient already antihypertensive therapy SBP randomization far target maintain current therapy suitable adjustment . Other patient ( untreated SBP far target ) may follow suggest treatment algorithm progressive increase number compound dos . During follow-up visit drug and/or dos modify necessary maintain patient within randomized target window . 2 . Lipid-lowering treatment design assign treatment Participants randomly allocate one two different LDL-C target : A ) 2.8 1.8 mmol/l ( 110 70 mg/dl ) B ) &lt; 1.8 mmol/l ( &lt; 70 mg/dl ) possibly achieve within 3 month subsequently maintain within target window . Investigators free choose statin ( among approve country ) administer individual patient . The initial statin dose choose investigator accord LDL-C randomization LDL-C target . The initial dose increase ( maximum dose allow country ) decrease LDL-C target achieve possibly within 3 month , adjust 6-month interval order maintain LDL-C within randomize target window .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemic Attack , Transient</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Enzyme Inhibitors</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Calcium Channel Blockers</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Qualifying event : stroke TIA 1 6 month previous randomization . All patient CT scan MRI ( preferably MRI ) screening . The CT scan MRI carry time qualify event , available , acceptable . Stroke define image evidence recent brain infarction ( haemorrhage ) independently duration clinical symptom , duration clinical symptom &gt; 24 h even absence image evidence lesion TIA clinical symptom ( involve limbs speech ) last &lt; 24 h without image evidence infarction . Enrolling unit avoid enrol patient TIA proportion great 25 % enrolled patient . The general coordinator Milan Beijing may decide stop enrolment TIA patient proportion become great expect . A haemorrhagic stroke ( 1 6 month previously ) also qualify event , BPlowering component trial ( see Exclusion criterion ) . Age : 65 year . No fixed upper age limit introduce , frail patient age 80 year enrol . Gender : either gender . BP : Only hypertensive patient : untreated patient SBP â‰¥140 mmHg ; patient antihypertensive treatment BP ( see exclusion criterion ) LDLC : Patients without statin treatment LDLC &gt; 2.8 mmol/l ; patient statin treatment LDLC value ( see exclusion criterion ) Antiplatelet therapy : All patient antiplatelet therapy ( agent dose choose investigator accord accepted guideline ) , unless contraindicate . Anticoagulant ( instead antiplatelet ) therapy whenever indicate ( e.g . atrial fibrillation ) . Qualifying event : 1 . Patients unstable clinical condition 2 . Clinical disturbance cause nonstroke pathology 3. patient haemodynamically significant carotid stenosis require carotid revascularization 4. haemorrhagic stroke exclusion criterion lipid lower component trial ; however , patient randomize BP component , consider addition number patient request enrol unit , order decrease power lipidlowering component . BP : know secondary hypertension ; SBP &gt; 140 mmHg three antihypertensive drug full dos ( patient unlikely achieve SBP &lt; 125 mmHg , randomize ) ; orthostatic hypotension ( SBP fall &gt; 25 mmHg standing ) ; LDLC : LDLC &gt; 2.8 mmol/l full dose statin ( patient unlikely achieve LDLC target ) . LDLC &gt; 4.5 mmol/l low dose statin untreated ( patient unlikely achieve low LDLC target ) . Others : Patients myocardial infarction ( precede subsequent qualify stroke TIA ) baseline LDLC &lt; 1.8 mmol/l Dementia Severe disability ( modify Rankin scale &gt; 4 ) Severe chronic renal failure define serum creatinine &gt; 250 micromol/l Hepatic disease determine either AST ALT value &gt; 2 time upper limit normal History hepatic encephalopathy , esophageal varix portocaval shunt History gastrointestinal surgery disorder could interfere drug absorption Known allergy contraindication one drug administer study History malignancy include leukaemia lymphoma ( basal cell skin cancer ) within last 5 year History clinically significant autoimmune disorder systemic lupus erythematosus History drug alcohol abuse within last 5 year History noncompliance medical regimen and/or patient consider potentially unreliable Inability unwillingness give free inform consent</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Blood pressure medicine</keyword>
	<keyword>Lipid lower medicine</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Stroke</keyword>
	<keyword>Dementia</keyword>
	<keyword>Heart attack</keyword>
	<keyword>Heart failure</keyword>
</DOC>